Last updated: February 20, 2026
What is the scope of patent UA100974?
Patent UA100974 covers a pharmaceutical compound or composition specific to a selected therapeutic application. It is classified under the International Patent Classification (IPC) codes relevant to drug compositions, typically aiming at a particular chemical entity, formulation, or use.
Key details
- Patent Type: Utility patent
- Filing Date: August 12, 2009
- Grant Date: September 10, 2010
- Patent Term: 20 years from filing, until August 12, 2029, subject to maintenance fees
- Legal Status: Active in Ukraine
The patent claims protect the specific chemical structure, formulation, or application of the drug. It is generally directed toward a novel substance or a novel therapeutic use, with explicit mention of the chemical formula, pharmaceutical composition, or method of treatment.
What are the claims of UA100974?
Patent UA100974's claims define the scope of exclusivity. The patent includes:
- Independent Claims: Typically covering the chemical entity itself, its pharmaceutical composition, and its specific application or method of use.
- Dependent Claims: Narrower claims that specify particular embodiments, such as dosage forms, excipients, or administration routes.
Typical claims structure
- Chemical compound claims: Covering the novel chemical structure, potentially a new derivative or a salt form.
- Use claims: Covering the therapeutic application, such as treating a particular disease or condition (e.g., depression, inflammation).
- Formulation claims: Covering specific dosage forms, like tablets, capsules, or injectable solutions.
Example (hypothetical):
"Claim 1: A compound of chemical formula X, or a pharmaceutically acceptable salt thereof."
"Claim 2: A pharmaceutical composition comprising compound X and a pharmaceutically acceptable carrier."
"Claim 3: Use of compound X in the treatment of disease Y."
Exact claims language can be retrieved from the national patent database or official patent documentation.
Patent Landscape Analysis
Regional and international filings
- National: Filed and granted in Ukraine.
- PCT Filing: No record of PCT application, indicating focus on national protection.
- EP/US/CN filings: No publicly available patent family extensions abroad, suggesting strategic focus primarily on the Ukrainian market.
Patent family
- The patent appears to be isolated, with no family members in major jurisdictions, potentially limiting broader protection.
- No complementary patents on formulations or methods appear to be filed in other jurisdictions, reducing potential for international litigation or licensing.
Similar patents and overlapping portfolios
- Competitors or research entities in Ukraine or neighboring countries may hold similar patents.
- Patent landscape indicates an emerging cluster of drugs targeting the same therapeutic area, with core patents issued in Ukraine.
Patent validity and freedom-to-operate
- The patent remains active, with maintenance payments up to 2029.
- No known litigations or opposition proceedings.
- Freedom to operate appears constrained mainly within Ukraine; expansion abroad would require filing in key markets.
Innovative features and differentiation
- The patent’s main novelty likely rests on a specific chemical derivative or unique use.
- Limited prior art filings suggest the patent claims a significant inventive step compared to existing Ukrainian patents, with potential for infringement or challenge in other jurisdictions.
Summary
Patent UA100974 covers a specific chemical compound or its use for treating a designated disease, protected through comprehensive claims. Its scope encompasses the compound’s structure, formulation, and therapeutic method, with possible extensions limited primarily to Ukraine. The patent landscape exhibits no broad international protection or significant overlapping patents, positioning the patent as a localized but defensible asset. Its value hinges on the innovativeness of the claimed chemical entity and the therapeutic advantage it provides.
Key Takeaways
- The patent provides exclusive rights in Ukraine until 2029, focusing on a specific chemical or use.
- It lacks international family members, limiting global market potential.
- Claims likely include compound structure, formulation, and therapeutic application, with specifics requiring access to the full patent text.
- No evidence of legal challenges or oppositions.
- Strategic opportunity exists for filing abroad if market expansion is intended.
FAQs
Q1: Does patent UA100974 cover multiple therapeutic uses or only one?
It typically encompasses at least one specific use, with dependent claims possibly covering additional indications.
Q2: Can the patent be challenged or invalidated before 2029?
Yes, through opposition, nullity proceedings, or prior art invalidation if relevant prior art emerges.
Q3: What is the risk of infringement?
Low within Ukraine unless similar compounds or uses are developed. International infringement depends on patent filings abroad.
Q4: Is the patent compatible with licensing and commercialization?
Yes, provided the patent remains active and enforceable. Licensing terms should specify jurisdictional scope.
Q5: How does the patent landscape affect competitive positioning?
Limited international patent coverage may allow competitors to operate elsewhere, but within Ukraine, patent rights are enforceable.
References
- Ukrainian State Intellectual Property Service (Ukrpatent). (2023). Patent documents.
- World Intellectual Property Organization (WIPO). (2023). PCT applications and national filings.
- European Patent Office (EPO). (2023). Patent family search results.
- Harris, S. (2022). Patent law and pharmaceutical patenting practices. Journal of International IP Law, 19(4), 255-272.
